<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164565</url>
  </required_header>
  <id_info>
    <org_study_id>104-12-EMC</org_study_id>
    <nct_id>NCT02164565</nct_id>
  </id_info>
  <brief_title>The Use of Tranexamic Acid (TXA) Intravenously, to Reduce Blood Loss in Proximal Femur Surgery</brief_title>
  <official_title>The Use of Tranexamic Acid (TXA) Intravenously, to Reduce Blood Loss in Proximal Femur Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of Tranexamic Acid (TXA) intravenously, to Reduce Blood Loss in proximal femur
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Enrollment difficulties
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of blood loss in ml.</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Hbloss=BV X (Hbi - Hbe) X 0.001 + Hbt Hbi - hemoglobin level before the surgery ) gram X liter-1(. Hbe - hemoglobin level 3 days after the surgery ( gram X liter-1). Hbt - The amount of hemoglobin that was given in the blood transfusion (gram). Hbloss - Change of hemoglobin loss.
After calculating the amount of loss of hemoglobin, the volume of blood lost can be found:
Blood loss = 1000 X Hbloss/ Hbi
Evaluation of blood loss will be through:
1. Comparing hemoglobin level before and after surgery and calculation of quantitative Change of hemoglobin loss.
2 .Registration evaluating blood loss at the end of surgery 3. Collecting and recording blood drain. 4. Tracking Blood Transfusion. Of course we collect the data: assessment of bleeding in the analysis, the number of blood units given, the amount of blood collected drain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Femur Surgery</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid (TXA) treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic Acid (TXA) treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control grup: without Tranexamic Acid (TXA) treatment.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>control grup: without Tranexamic Acid (TXA) treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid (TXA) treatment</intervention_name>
    <description>Tranexamic Acid (TXA) treatment</description>
    <arm_group_label>Tranexamic Acid (TXA) treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control grup: without Tranexamic Acid (TXA) treatment.</intervention_name>
    <description>control grup: without Tranexamic Acid (TXA) treatment.</description>
    <arm_group_label>control grup: without Tranexamic Acid (TXA) treatment.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 60, who came to the orthopedic department for proximal femur fracture
             surgery

          -  Sound judgment

        Exclusion Criteria:

          -  Known hypersensitivity to Tranexamic Acid or component solution provided

          -  Subarachnoid hemorrhage

          -  Acquired color blindness

          -  Myocardial infarction in 12 months before admission

          -  Unstable angina

          -  Known clotting disorders (Thromboembolic disease in the past, elongated PT and PTT,
             hypercoagulability),

          -  Kidney or liver failure

          -  Another situation prostate resection , pathologic fractures according to anamnesis or
             by imaging

          -  Oncology patients

          -  Patients on anticoagulation

          -  Patients undergoing vascular intervention ( coronary or peripheral ), which was
             inserted Supporter requires a Dual antiplatelet therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nimrod Rozen, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Orthopedic &amp; Rehabilitatio, HaEmek Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orthopedic Department, HaEmek Medical Center</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <last_update_submitted>August 13, 2017</last_update_submitted>
  <last_update_submitted_qc>August 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

